Objective
Cardiovascular disease (VD) is the leading cause of mortality and morbidity in Europe and worldwide. The objective of the PRETREAT consortium is to generate a joint SME/academic European preclinical platform for providing services for detection of VD and drug development. This platform will combine the use of urinary and/or blood peptidomics in humans and in preclinical animal models of VD, together with bioinformatics and systems biology, in order to better detect, stratify and decipher the molecular mechanisms of VD, develop new animal models with high similarity to human disease, and provide new tools for obtaining information on novel drug targets.
PRETREAT builds on the FP7 project Sysvasc (systems biology to identify molecular targets for vascular disease treatment, 2014-2018) and the combined expertise of the PRETREAT partners in clinical proteomics, proteomics, animal models and system medicine as the pillars to implement this platform. The work will be carried out in an extensive exchange program totaling 27 secondments. Main objectives during the secondments include establishment of the link between urinary markers and the pathophysiology of VD, identification of additional animal VD models with similarity to human VD, development of “humanized” body fluid readouts in VD models, establishment of a VD protein-centric database in order to automatically link urinary peptides to in situ changes and provide information on drug targets, and provide proof-of-concept of the utility of the proposed platform. These secondments will in parallel serve to keep information flowing within the project, increase individual research efficiency and create a multi-disciplinary working chain, train personnel, and prepare the sustainability of the results after the project. To complete training, 3 monthly webinars and four workshops are planned.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineangiologyvascular diseases
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
Programme(s)
Coordinator
75654 Paris
France
See on map
Participants (4)
30659 Hannover
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
115 27 Athina
See on map
Participation ended
1180 Vienna
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
166 72 Vari
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.